Dr. Reddy's Laboratories Limited (DRREDDY.BO)
| Previous Close | 6,293.50 |
| Open | 6,293.65 |
| Bid | 6,189.00 x 0 |
| Ask | 6,211.25 x 0 |
| Day's Range | 6,188.55 - 6,310.15 |
| 52 Week Range | 4,383.40 - 6,505.50 |
| Volume | |
| Avg. Volume | 13,078 |
| Market Cap | 1.033T |
| Beta (5Y Monthly) | 0.34 |
| PE Ratio (TTM) | 19.80 |
| EPS (TTM) | 313.36 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | 40.00 (0.64%) |
| Ex-Dividend Date | Jul 11, 2023 |
| 1y Target Est | 2,581.68 |
GlobeNewswirePharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
Centhaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in (afterload) due to arterial dilatationIndia is the first global territory where Centhaquine is being launched immediately WILLOWBROOK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. ("Pharmazz"), a biopharmaceutical company developing and commercializing drug products to treat c
Business WireDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
HYDERABAD, India, March 19, 2024--Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, announced the launch of Versavo® (bevacizumab) in the United Kingdom (UK).
ZacksWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
